Head-To-Head Contrast: Liquidia (NASDAQ:LQDA) and SCYNEXIS (NASDAQ:SCYX)

Liquidia (NASDAQ:LQDA – Get Free Report) and SCYNEXIS (NASDAQ:SCYX – Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, earnings, valuation and dividends.

Risk and Volatility

Liquidia has a beta of 0.61, suggesting that its stock price is 39% less volatile than the S&P 500. Comparatively, SCYNEXIS has a beta of 1.06, suggesting that its stock price is 6% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Liquidia and SCYNEXIS, as provided by MarketBeat.

Liquidia presently has a consensus target price of $72.85, suggesting a potential upside of 113.44%. SCYNEXIS has a consensus target price of $33.00, suggesting a potential upside of 801.64%. Given SCYNEXIS’s higher possible upside, analysts clearly believe SCYNEXIS is more favorable than Liquidia.

Profitability

This table compares Liquidia and SCYNEXIS’s net margins, return on equity and return on assets.

Insider and Institutional Ownership

64.5% of Liquidia shares are owned by institutional investors. Comparatively, 54.4% of SCYNEXIS shares are owned by institutional investors. 25.6% of Liquidia shares are owned by insiders. Comparatively, 4.1% of SCYNEXIS shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Liquidia and SCYNEXIS”s top-line revenue, earnings per share (EPS) and valuation.

SCYNEXIS has lower revenue, but higher earnings than Liquidia. SCYNEXIS is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks.

Summary

Liquidia beats SCYNEXIS on 12 of the 15 factors compared between the two stocks.

About Liquidia

(Get Free Report)

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

About SCYNEXIS

(Get Free Report)

SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.